Literature DB >> 6786827

Plasma levels of levonorgestrel in women during longterm use of norplant.

H B Croxatto, S Díaz, P Miranda, K Elamsson, E D Johansson.   

Abstract

Levonorgestrel plasma levels were determined by a specific radioimmunoassay in a group of 110 women at various intervals between 1 and 60 months following implantation of six silastic capsules containing levonorgestrel (Norplant). The implants were placed subdermally in the volar aspect of the forearm. Blood samples were taken twice a week for six consecutive weeks in each subject. Blood drawn from the antecubital vein ipsilateral to the implant site contained two to three times more levonorgestrel than contralateral samples. Average systemic plasma levels represented by contralateral samples ranged from 0.35 +/- 0.03 to 0.29 +/- 0.02 ng/ml (Mean +/- S.E.) in the first and fifth year, respectively. The difference between these values is statistically significant at the 5% level. The results of the regression analysis of individual levels suggest that the decline observed throughout the first five years is mainly due to an early decrease taking place in the first two years. When the sampling period was repeated in the same subjects two or three times 10 to 24 months apart, no significant difference was found. A significant negative correlation was found between plasma levonorgestrel levels and body weight and body surface. The data indicate that the contraceptive efficacy of Norplant during the first five years of use is associated with sustained release of levonorgestrel and is in keeping with the estimated life span of Norplant of seven years.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6786827     DOI: 10.1016/0010-7824(81)90105-0

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Facts about an implantable contraceptive: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

3.  [Concerning an implantable contraceptive: a memorandum of a WHO meeting].

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

4.  Comparison of plasma etonogestrel concentrations sampled from the contralateral-to-implant and ipsilateral-to-implant arms of contraceptive implant users.

Authors:  Alida M Gertz; Ian J Bishop; Boikhutso Simon; Kwana Lechiile; Opelo Badubi; Aamirah Mussa; Carolyn L Westhoff; Chelsea Morroni
Journal:  Contraception       Date:  2020-08-26       Impact factor: 3.375

Review 5.  Controlled-release delivery systems for hormones. A review of their properties and current therapeutic use.

Authors:  L R Beck; V Z Pope
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.

Authors:  Andrea R Thurman; Vivian Brache; Leila Cochon; Louise A Ouattara; Neelima Chandra; Terry Jacot; Nazita Yousefieh; Meredith R Clark; Melissa Peet; Homaira Hanif; Jill L Schwartz; Susan Ju; Mark A Marzinke; David W Erikson; Urvi Parikh; Betsy C Herold; Raina N Fichorova; Elizabeth Tolley; Gustavo F Doncel
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

Review 7.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

8.  Controlled release of contraceptive steroids from biodegradable and injectable gel formulations: in vivo evaluation.

Authors:  Z H Gao; W R Crowley; A J Shukla; J R Johnson; J F Reger
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

9.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.